Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSONASDAQ:ICCMNASDAQ:XAIRNASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$1.16-3.3%$0.98$0.70▼$1.61$72.63M1.05147,312 shs44,051 shsICCMIceCure Medical$0.95+0.8%$1.07$0.48▼$1.66$52.73M0.33469,709 shs125,625 shsXAIRBeyond Air$0.20-29.0%$0.20$0.16▼$1.49$17.47M0.231.50 million shs10.73 million shsZYXIZynex$2.41+2.1%$2.23$1.66▼$10.62$72.88M0.82165,270 shs157,306 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents0.00%+8.41%+38.06%+17.95%+54.05%ICCMIceCure Medical0.00%-4.04%-6.86%-24.00%+20.41%XAIRBeyond Air0.00%+10.37%+5.04%-24.57%-83.94%ZYXIZynex0.00%+16.43%-2.43%-1.63%-73.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents1.7067 of 5 stars3.52.00.00.01.80.00.6ICCMIceCure Medical2.4518 of 5 stars3.85.00.00.00.60.00.6XAIRBeyond Air4.2351 of 5 stars3.54.00.03.52.00.81.3ZYXIZynex1.9998 of 5 stars3.20.00.00.00.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$5.50374.14% UpsideICCMIceCure Medical 3.50Strong Buy$2.50163.16% UpsideXAIRBeyond Air 3.00Buy$1.50641.47% UpsideZYXIZynex 2.33Hold$6.00148.96% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, ZYXI, ICCM, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.505/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.004/30/2025ZYXIZynexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.004/15/2025ZYXIZynexRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.60M2.04N/AN/A$0.20 per share5.80ICCMIceCure Medical$3.29M16.03N/AN/A$0.12 per share7.92XAIRBeyond Air$3.70M4.72N/AN/A$0.75 per share0.27ZYXIZynex$192.35M0.38$0.24 per share9.87$1.12 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)ICCMIceCure Medical-$15.32M-$0.28N/AN/AN/A-467.37%-182.26%-112.65%8/19/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,258.46%-213.97%-104.66%8/5/2025 (Estimated)ZYXIZynex$2.99M-$0.24N/A5.13N/A-4.30%-23.70%-6.23%7/23/2025 (Estimated)Latest XAIR, ZYXI, ICCM, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million5/28/2025Q1 2025ICCMIceCure Medical-$0.08-$0.06+$0.02-$0.06$0.75 million$0.73 million5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million4/28/2025Q1 2025ZYXIZynex-$0.24-$0.33-$0.09-$0.33$30.83 million$26.58 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/27/2025Q4 2024ICCMIceCure Medical-$0.07-$0.08-$0.01-$0.08$1.07 million$1.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents0.982.612.30ICCMIceCure Medical0.021.891.48XAIRBeyond AirN/A3.563.12ZYXIZynex2.873.462.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%ICCMIceCure Medical0.62%XAIRBeyond Air31.50%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%ICCMIceCure Medical2.44%XAIRBeyond Air19.40%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.61 million58.04 millionOptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableXAIRBeyond Air7086.37 million69.61 millionOptionableZYXIZynex77030.24 million15.34 millionOptionableXAIR, ZYXI, ICCM, and CTSO HeadlinesRecent News About These CompaniesZynex (NASDAQ:ZYXI) Stock Price Down 3.9% - What's Next?May 30, 2025 | marketbeat.comHere’s Why Zynex (ZYXI) Fell in Q1May 23, 2025 | msn.comZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens BermanMay 21, 2025 | morningstar.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexMay 21, 2025 | tmcnet.comZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 ...May 19, 2025 | gurufocus.comLost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class ActionMay 19, 2025 | accessnewswire.comZynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff MotionMay 19, 2025 | globenewswire.comZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud LawsuitMay 19, 2025 | prnewswire.comZYXI Investors Have Opportunity to Lead Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. ...May 19, 2025 | gurufocus.comZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025May 19, 2025 | accessnewswire.comZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 19, 2025 | businesswire.comZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 19, 2025 | globenewswire.comZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action – ZYXIMay 19, 2025 | globenewswire.comInvestors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending ...May 19, 2025 | gurufocus.comMay 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXIMay 19, 2025 | globenewswire.comInvestors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXIMay 19, 2025 | prnewswire.comSecurities Lawsuit Alert: Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky Before May 19, 2025May 19, 2025 | accessnewswire.comMay 19, 2025 Deadline: Join Class Action Lawsuit Against Zynex, Inc. (ZYXI) - Contact Levi & KorsinskyMay 19, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXIMay 19, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, ZYXI, ICCM, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$1.16 -0.04 (-3.33%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.11 -0.05 (-4.66%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.IceCure Medical NASDAQ:ICCM$0.95 +0.01 (+0.76%) Closing price 06/18/2025 03:56 PM EasternExtended Trading$0.97 +0.02 (+1.68%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Beyond Air NASDAQ:XAIR$0.20 -0.08 (-29.02%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.21 +0.01 (+4.30%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.Zynex NASDAQ:ZYXI$2.41 +0.05 (+2.12%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.37 -0.04 (-1.66%) As of 06/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
